Equity Issuances

Cottonwood Communities, Inc. issued 265,644 shares of Series A Convertible Preferred Stock of preferred stock to accredited investors for aggregate proceeds of $2,570,100.

“During the period from February 27, 2026 through March 10, 2026, we issued and sold 265,644 shares of Series A Convertible Preferred Stock in the Series A Convertible Private Offering and received aggregate proceeds of $2,570,100.”

IonQ, Inc. issued an aggregate of 2,562,642 shares of Company common stock of common stock to The Chancellor, Masters, and Scholars of the University of Cambridge.

“The issuance of shares of common stock of the Company, par value $0.0001 per share, in connection with the transaction was made in reliance on the private offering exemption of Section 4(a)(2) of the Securities Act of 1933, as amended, and/or the private offering provision of Rule 506 of Regulation D.”

SunPower Inc. issued convertible note to YA II PN, LTD. for principal amount of $10,000,000 for a purchase price of $9,000,000.

“of which is filed herewith as Exhibit 10.1. Pursuant to the Purchase Agreement, the Investor purchased and the Company issued a convertible debenture in the principal amount of $10,000,000 (the “ Debenture ”). At the closing under the Purchase Agreement, the Company issued the Debenture to the Investor in the original principal amount of $10,000,000 for a purchase”

Calidi Biotherapeutics, Inc. issued 604,732 shares of warrant to underwriter for sold to Underwriter in connection with the Offering.

“In connection with the Offering, the Company also issued to the Underwriter (or its designees) a warrant (the “Underwriter’s Warrant”) to purchase up to 604,732 shares of common stock of the Company, par value $0.0001 (the “Common Stock”).”

Calidi Biotherapeutics, Inc. issued 9,815,900 pre-funded warrant units of preferred stock to public for $0.499 per Pre-Funded Unit, part of gross proceeds of $6.03 million.

“On March 6, 2026, Calidi Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as sole underwriter (“Underwriter”), in connection with the issuance and sale (the “Offering”) of: (i) 2,278,731 common stock units (“Common Stock Units”), which includes 1,575,000 Common Stock Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) 9,815,900 pre-funded warrant units (“Pre-Funded Units”), resulting in gross proceeds of approximately $6.03 million”

Calidi Biotherapeutics, Inc. issued 2,278,731 Common Stock Units of unit to public for $0.50 per Common Stock Unit, gross proceeds of approximately $6.03 million.

“On March 6, 2026, Calidi Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as sole underwriter (“Underwriter”), in connection with the issuance and sale (the “Offering”) of: (i) 2,278,731 common stock units (“Common Stock Units”), which includes 1,575,000 Common Stock Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) 9,815,900 pre-funded warrant units (“Pre-Funded Units”), resulting in gross proceeds of approximately $6.03 million”

CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $750,000.

“On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).”

Helio Corp /FL/ issued 1,000 shares of preferred stock to an investor (the "Purchaser") for aggregate purchase price of $931,500.

“On March 5, 2026, Helio Corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an investor (the “ Purchaser ”), pursuant to which the Company sold to the Purchaser 1,000 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), for an aggregate purchase price of $931,500.”

Aureus Greenway Holdings Inc issued placement agent warrants to purchase a number of shares of Common Stock equal to 8.0% of the aggregate number of shares of Common Stock sold in the Private Plac of warrant to Dominari Securities LLC, as placement agent (the “ Placement Agent ”), and to Revere Securities LLC for certain cash fees and expense reimbursements.

“In connection with the Private Placement, the Company also issued to Dominari Securities LLC, as placement agent (the “ Placement Agent ”), and to Revere Securities LLC placement agent warrants to purchase a number of shares of Common Stock equal to 8.0% of the aggregate number of shares of Common Stock sold in the Private Placement (inclusive of shares underlying the Pre-Funded Warrants), at an exercise price of $3.00 per share, exercisable immediately upon issuance and expiring five years from the date of issuance, together with certain cash fees and expense reimbursements as previously described in the March 9 8-K.”

Aureus Greenway Holdings Inc issued 3,009,667 shares of Common Stock and/or Pre-Funded Warrants of common stock to institutional and accredited investors for $3.00 per share (or $3.00 per Pre-Funded Warrant), for gross proceeds of approximately $9.0 million.

“On March 10, 2026, the Company issued and sold to the Purchasers an aggregate of 3,009,667 shares of Common Stock and/or Pre-Funded Warrants at a purchase price of $3.00 per share (or $3.00 per Pre-Funded Warrant), for gross proceeds of approximately $9.0 million before deducting placement agent fees and other offering expenses.”

Elite Express Holding Inc. issued 32,000,000 shares of Class A Common Stock of common stock to eight non-U.S. investors for purchase price per share of $0.25, aggregate gross proceeds of $8,000,000.

“On March 10, 2026, Elite Express Holding Inc., a Delaware corporation (the “Company” ), entered into a Stock Purchase Agreement (the “Purchase Agreement” ) with eight non-U.S. investors (the “Purchasers” ), pursuant to which the Company agreed to issue and sell in a private placement offering (the “Private Placement” ) an aggregate of 32,000,000 shares (the “Shares” ) of the Company's Class A Common Stock, $0.000001 par value per share, at a purchase price per share of $0.25, for aggregate gross proceeds of $8,000,000.”

Clean Energy Technologies, Inc. issued convertible note to Noblebear Investment Holdings LLC for principal amounts of $660,000.

“agreements with Mega and Noblebear (the “ Mega and Noblebear SPA’s ”) and issued Mega and Noblebear convertible promissory notes in the principal amounts of $664,916 and $660,000, respectively (the “ Mega and Noblebear Notes ”). The Mega and Noblebear SPA’s include customary representations, warranties and covenants by the Company. Each of the Mega”

Clean Energy Technologies, Inc. issued convertible note to Mega Sincere Holdings Limited for principal amounts of $664,916.

“securities purchase agreements with Mega and Noblebear (the “ Mega and Noblebear SPA’s ”) and issued Mega and Noblebear convertible promissory notes in the principal amounts of $664,916 and $660,000, respectively (the “ Mega and Noblebear Notes ”). The Mega and Noblebear SPA’s include customary representations, warranties and covenants by the Company. Each of the”

Clean Energy Technologies, Inc. issued convertible note to 1800 Diagonal Lending LLC for purchase price of $132,000.

“On or about March 4, 2026, Clean Energy Technologies, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ 1800 SPA ”) with 1800 Diagonal Lending LLC, a Virginia limited liability company (“ 1800 Diagonal ”), pursuant to which the Company sold, and 1800 Diagonal purchased, a convertible promissory note in the principal amount of $147,840 (the “ 1800 Note ”) for a purchase price of $132,000”

CV Sciences, Inc. issued convertible note to institutional investor.

“the Company will issue a new senior secured convertible note on substantially the same terms and conditions of the Amended Notes (the “Third Note”) with a principal amount equal to the aggregate shortfall in excess of $94,000”

CV Sciences, Inc. issued convertible note to institutional investor for $2,256,000 aggregate outstanding principal amount.

“amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion”

Edible Garden AG Inc issued 175,165 shares of the Company's common stock of common stock to Streeterville Capital, LLC.

“On February 9, 2026, March 4, 2026, March 9, 2026 and March 10, 2026, Edible Garden AG Incorporated (the “Company”) entered into exchange agreements (the “Exchange Agreements”) with Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”) pursuant to which the Company agreed to exchange 90, 192, 65 and 133 shares, respectively, of the Company’s Series B Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), for a total of 175,165 shares of the Company’s common stock, par value $0.0001 per share (“Exchange Shares”).”

Sono Group N.V. issued up to 283,367 Ordinary Shares of warrant to YA II PN, Ltd. (Yorkville) for $2,000,004.29 aggregate.

“At the closing of the Private Placement (the “Closing”), which occurred on March 10, 2026, the Company issued and sold to Yorkville a pre-funded warrant to purchase up to 283,367 Ordinary Shares of the Company (the “Warrant Shares”), exercisable in whole or in part at any time after issuance (the “Pre-Funded Warrant”). The aggregate subscription amount for the Pre-Funded Warrant was $2,000,004.29.”

PMGC Holdings Inc. issued 1-for-6 reverse stock split of common stock.

“PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-6 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on March 10, 2026.”

AN2 Therapeutics, Inc. issued 5,789,493 shares of Common Stock of warrant to certain investors for $2.84999 per Pre-Funded Warrant.

“of 5,789,493 shares of Common Stock (the “Pre-Funded Warrants,” and, together with the Shares, the “Securities”) (collectively, the “Private Placement”). The price per Share is $2.85, and the price per Pre-Funded Warrant is $2.84999. The closing of the Private Placement is expected to occur on March 10, 2026 (the “Closing”). The Pre-Funded Warrants have an”

AN2 Therapeutics, Inc. issued 8,245,611 shares of common stock to certain investors for $2.85 per share.

“of 5,789,493 shares of Common Stock (the “Pre-Funded Warrants,” and, together with the Shares, the “Securities”) (collectively, the “Private Placement”). The price per Share is $2.85, and the price per Pre-Funded Warrant is $2.84999. The closing of the Private Placement is expected to occur on March 10, 2026 (the “Closing”). The Pre-Funded Warrants have an”

ISQ Open Infrastructure Co LLC issued Class I F-S TE Shares 14,224 of common stock to accredited investors and non-U.S. investors for Aggregate Net Consideration $13,584,350.

“February 1, 2026 held by third parties. * Share and dollar amounts rounded to the nearest whole number. The Company issued such shares for total aggregate net consideration of $13,584,350 (the “Proceeds”). The offer and sale of the shares above were exempt from the registration provisions of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2),”

STRATEGIC ACQUISITIONS INC /NV/ issued 10,000,000 new restricted common shares of common stock to Jennifer L. O'Shea for subscription price of $0.001 for past services rendered.

“Strategic Acquisitions, Inc. (the “Company” or the “Registrant”) Board of Directors approved the issuance of 10,000,000 new restricted common shares to Jennifer L. O’Shea at subscription price of $0.001 for past services rendered to the Company.”

STRATEGIC ACQUISITIONS INC /NV/ issued 30,000,000 new restricted common shares of common stock to John P. O'Shea for subscription price of $0.001 for past services rendered.

“Strategic Acquisitions, Inc. (the “Company”) Board of Directors approved the issuance of 30,000,000 new restricted common shares to John P. O’Shea at subscription price of $0.001 for past services rendered to the Company.”

GUIDED THERAPEUTICS INC issued 4,825,000 shares of common stock to holders of Eligible Warrants.

“on March 2, 2026, the Company issued an aggregate of 4,825,000 shares of Common Stock to holders of Eligible Warrants.”

BATTALION OIL CORP issued up to 927,273 shares of Common Stock of warrant to an institutional investor for $5.4999 per Pre-funded Warrant share.

“pre-funded warrants to purchase up to 927,273 shares of Common Stock (the “ Pre-funded Warrants ”) at a purchase price of $5.4999 per Pre-funded Warrant share”

BATTALION OIL CORP issued 1,800,000 shares of common stock to an institutional investor for $5.50 per Share.

“the Company agreed to sell and the Purchaser agreed to purchase from the Company, in a private placement offering, 1,800,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) at a purchase price of $5.50 per Share”

Bunker Hill Mining Corp. issued 159,735,000 units of unit to accredited investors for C$0.18 per unit.

“in Canada (excluding Québec), the United States and jurisdictions outside of Canada and the United States. The Company issued the LIFE Units at a price per LIFE Unit of C$0.18 (the “ Offer Price ”) for gross proceeds of approximately C$33,752,300 (which includes the full exercise of the agents’ over-allotment option and the proceeds received pursuant to”

BARFRESH FOOD GROUP INC. issued 100% of their investment amounts of warrant to accredited investors for $3.20 per share.

“Purchasers of the Notes were issued warrants to purchase common stock (the “Warrants’) at a price of $3.20 per share (the “Exercise Price”) for a 4-year term from date of issuance in an amount equal to 100% of their investment amounts.”

BARFRESH FOOD GROUP INC. issued convertible note to accredited investors for aggregate amount of $7,278,000.

“On March 5, 2026, the registrant obtained subscriptions for unsecured senior convertible promissory notes in the aggregate amount of $7,278,000 (the “Notes”) from accredited investors.”

RELMADA THERAPEUTICS, INC. issued up to 4,210,527 shares of Common Stock of warrant to certain institutional and accredited investors for $4.749 per Pre-Funded Warrant.

“of approximately $160.0 million, an aggregate of (i) 29,474,569 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.75 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,210,527 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a price of $4.749 per”

RELMADA THERAPEUTICS, INC. issued 29,474,569 shares of common stock to certain institutional and accredited investors for $4.75 per Share.

“of approximately $160.0 million, an aggregate of (i) 29,474,569 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.75 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,210,527 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a price of $4.749 per”

Envirotech Vehicles, Inc. issued 1,291,778 shares of warrant to YA II PN, Ltd. for commitment fee.

“the Company issued to the Buyer warrants to purchase up to 1,291,778 shares of Common Stock at an exercise price of $0.01 per share”

SS Innovations International, Inc. issued warrants to purchase 41,667 shares of our common stock of warrant to a FINRA member firm for exercise price of $3.45 per share.

“the Company will pay a FINRA member firm a cash commission of $175,000 (7% of the investment) and issue to such firm five-year warrants to purchase 41,667 shares of our common stock at an exercise price of $3.45 per share”

SS Innovations International, Inc. issued 4,474,833 shares of common stock of common stock to existing and new investors, led by Manipal Global Health Services for at $3.00 per share for a total of approximately $13.4 million.

“an aggregate of 4,474,833 shares of common stock at $3.00 per share for a total of approximately $13.4 million, to existing and new investors, led by Manipal Global Health Services”

SS Innovations International, Inc. issued 1,300,006 shares of common stock to Dr. Sudhir Srivastava, Dr. Frederic Moll, and Tim Adams for at an average price of $4.00 per share for a total of approximately $5.2 million.

“an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share for a total of approximately $5.2 million, to Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer (498,753 shares at $4.01 per share for a total of $2.0 million), Dr. Frederic Moll, our Vice Chairman (501,253 shares at $3.99 per share for a total of $2.0 million), and Tim Adams, a director (300,000 shares at $3.99 per share for a total of $1.2 million)”

Midnight Gaming Corp issued warrant.

“Effective as of March 8, 2026, the Company materially modified the rights of the holders of the Midnight Warrants outstanding at the effective time by adding a universal cashless exercise right applicable to all such warrants”

Korro Bio, Inc. issued 3,148,836 shares of warrant to institutional accredited investors for $11.109 per pre-funded warrant.

“pre-funded warrants to acquire an aggregate of 3,148,836 shares of its common stock at a purchase price of $11.109 per pre-funded warrant”

Korro Bio, Inc. issued 4,501,928 shares of common stock to institutional accredited investors for $11.11 per share.

“4(a)(2) of the Securities Act of 1933, as amended, or the 1933 Act: (i) an aggregate of 4,501,928 shares of its common stock, par value $0.001 per share at a purchase price of $11.11 per share and (ii) pre-funded warrants to acquire an aggregate of 3,148,836 shares of its common stock at a purchase price of $11.109 per pre-funded warrant. The private placement”

Catheter Precision, Inc. issued 1,853 shares of Series C-3 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.00.

“pursuant to the Financing Purchase Agreement, the Purchasers agreed to purchase (i) 1,853 shares of the Company’s newly-designated Series C-2 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-2 Preferred Stock”), and (ii) 1,853 shares of the Company’s newly-designated Series C-3 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-3 Preferred Stock” and, together with the Series C-1 Preferred Stock and Series C-2 Preferred Stock, the “Initial Preferred Stock”)”

Catheter Precision, Inc. issued 1,853 shares of Series C-2 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.00.

“pursuant to the Financing Purchase Agreement, the Purchasers agreed to purchase (i) 1,853 shares of the Company’s newly-designated Series C-2 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-2 Preferred Stock”), and (ii) 1,853 shares of the Company’s newly-designated Series C-3 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-3 Preferred Stock” and, together with the Series C-1 Preferred Stock and Series C-2 Preferred Stock, the “Initial Preferred Stock”)”

Catheter Precision, Inc. issued 1,853 shares of Series C-1 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.

“On March 9, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of 1,853 shares of the Company’s Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,295,805 shares of common stock, par value $0.0001 per share (“Common Stock”), at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock”) for an aggregate purchase price of $1,853,000”

Brand Engagement Network Inc. issued 24,000 shares of common stock to Ben Capital Fund I, LLC for $63.25 per share.

“the financing consisted of the sale of 24,000 shares of the Company’s common stock at a purchase price of $63.25 per share , funded in three equal installments of $506,000 each”

Dave Inc./DE issued convertible note to initial purchasers for $200 million aggregate principal amount.

“On March 5, 2026, the initial purchasers elected to exercise the option in full and a total of $200 million aggregate principal amount of Notes were issued on March 9, 2026.”

Crescent Energy Co issued convertible note to Initial Purchasers for $690 million aggregate principal amount.

“On March 6, 2026, Crescent Energy Company, a Delaware corporation (NYSE: CRGY) (the “Company”), issued $690 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2031 (the “Notes”), which included the exercise in full of the Initial Purchasers’ (as defined below) option to purchase up to an additional $90 million principal amount of Notes.”

Alternus Clean Energy, Inc. issued 400 shares of Series C Convertible Preferred Stock of preferred stock to existing third party accredited debt holders for total repayment for, and cancellation of, an outstanding payable in the amount of $1,200,000.

“(ii) 400 shares of Series C Convertible Preferred Stock as total repayment for, and cancellation of, an outstanding payable in the amount of $1,200,000”

Alternus Clean Energy, Inc. issued 2,750 shares of Series C Convertible Preferred Stock of preferred stock to existing third party accredited debt holders for total repayment for, and the cancellation of, outstanding promissory notes in the aggregate amount of $2,750,000.

“the Company settled with two existing third party accredited debt holders, pursuant to which the Company issued (i) 2,750 shares of Series C Convertible Preferred Stock as total repayment for, and the cancellation of, outstanding promissory notes in the aggregate amount of $2,750,000”

Alternus Clean Energy, Inc. issued 2,625 shares of the Company’s Series C Convertible Preferred Stock of preferred stock to certain investors (the "Purchasers").

“The Subscription Agreements also provide for the issuance of an aggregate of 2,625 shares of the Company’s Series C Convertible Preferred Stock, convertible into the Company’s common stock, par value $0.0001 per share (the “Shares”) to the Purchasers.”

Alternus Clean Energy, Inc. issued convertible note to certain investors (the "Purchasers") for $1,000,000 gross proceeds.

“par value $0.0001 per share (the “Shares”) to the Purchasers. The transaction closed on March 3, 2026 (the “Closing Date”). The aggregate gross proceeds to the Company were $1,000,000, $600,000 of such proceeds were transferred on the Closing Date and the remaining amount will be transferred to the Company in two tranches: the first tranche upon the Company’s”

Mag Magna Corp issued 40,575 shares of Common Stock of warrant to Lambda Ventures, LLC.

“Lambda was also issued a five-year warrant (the "Lambda Warrant") to purchase 40,575 shares of Common Stock with standard anti-dilution provisions and cashless exercise”